-
Chinese medical journal · Nov 2020
Randomized Controlled Trial Multicenter StudySecukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
- Lin Cai, Jian-Zhong Zhang, Xu Yao, Jun Gu, Quan-Zhong Liu, Min Zheng, Shi-Fa Zhang, Jin-Hua Xu, Cheng-Xin Li, Hao Cheng, Qing Guo, Wei-Li Pan, Shen-Qiu Li, Ruo-Yu Li, Zai-Pei Guo, Zhi-Qi Song, Shan-Shan Li, Xiu-Qin Dong, Linda Wang, Rong Fu, Pascaline Regnault, Pascal Charef, Rafal Mazur, and Manmath Patekar.
- Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
- Chin. Med. J. 2020 Nov 20; 133 (22): 2665-2673.
BackgroundPsoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis.MethodsThis study was a 52-week, multicentre, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 trial. A sub-population of study participants (≥18 years) of Chinese ethnicity were randomized to receive subcutaneous injections of 300 or 150 mg secukinumab, or placebo. The co-primary endpoints were psoriasis area severity index (PASI) 75 and Investigator's Global Assessment (IGA) 0/1 at Week 12.ResultsA total of 441 Chinese patients were enrolled in this study. Co-primary outcomes were achieved; 300 and 150 mg secukinumab were superior to placebo as shown in the proportion of patients that achieved PASI 75 (97.7% and 87.2% vs. 3.7%, respectively; P < 0.001), and IGA 0/1 (82.3% and 69.7% vs. 2.7%; P < 0.001) at Week 12. Treatment efficacy was maintained until Week 52. There was no increase in overall adverse events with secukinumab relative to placebo throughout the 52-week period.ConclusionSecukinumab is highly effective and well tolerated in Chinese patients with moderate to severe plaque psoriasis.Trial RegistrationClinicalTrials.gov, NCT03066609; https://clinicaltrials.gov/ct2/show/record/NCT03066609.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:

- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.